Charles River Laboratories International, Inc. is a non-clinical drug development partner providing products and services for the discovery, safety assessment, and manufacturing of pharmaceuticals, biologics, and other life science products. The company operates through three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. RMS supplies purpose-bred rodents, non-human primates, and genetically engineered models, along with services such as Insourcing Solutions, Genetically Engineered Models and Services (GEMS), and Research Animal Diagnostic Services (RADS). DSA offers outsourced drug discovery, non-clinical development, and regulated safety testing for small and large molecules, cell and gene therapies, vaccines, and medical devices. The Manufacturing segment includes Microbial Solutions for quality control testing and Biologics Solutions, which encompasses specialized testing and contract development and manufacturing for cell and gene therapies. The company serves pharmaceutical and biotechnology companies, academic institutions, government agencies, and industrial clients globally. Founded in 1947 and incorporated in 1994, the company completed its initial public offering in 2000.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Diagnostics & Research Homepage criver.com
Sector Healthcare IR page ir.criver.com
Tags
non-clinical drug development, research models, safety assessment, genetically engineered models, cell and gene therapies, contract research, biologics testing, microbial solutions, laboratory animal medicine, drug discovery, Research Models and Services, Discovery and Safety Assessment, Manufacturing Solutions, Insourcing Solutions, CRADL, Genetically Engineered Models and Services, GEMS, Research Animal Diagnostic Services, RADS, Cell Solutions, Biologics Solutions, Biologics Testing Solutions, K.F. (Cambodia) Ltd.
Press page —

Metrics

Valuation  
Market cap $ 16.757B
Market cap (USD) $ 16.757B
P/E 364.58
PEG —
P/BV 5.19
P/S 4.21
P/OCF 26.92
P/FCF 41.93
Dividend yield —
Turnover / mcap —
Returns  
ROE -4.4%
ROI -2.7%
ROIC 0.36%
Profit margin -3.6%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 66.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 53
Quality score -38.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 4.015B 4.05B 4.129B 3.976B 3.54B 2.924B 2.621B 2.266B 1.858B 1.681B 1.363B 1.298B 1.166B 1.13B 1.143B 1.133B 1.203B 1.343B 1.231B 1.058B 1.122B 766.917M 613.723M 554.629M 465.63M 306.585M
Net profit -144.338M 22.203M 474.624M 486.226M 390.982M 364.304M 252.019M 226.373M 123.355M 154.765M 149.313M — 104.151M 97.866M 109.977M -336.669M 114.441M -521.843M 154.406M -55.783M 141.999M 89.792M 80.151M 50.132M 35.407M -11.224M
Free cash flow 518.494M 501.61M 365.37M 294.907M 532.027M 380.015M 340.422M 301.086M 235.643M 245.087M 224.982M 195.207M 169.891M 160.472M 157.699M 125.376M 137.426M 82.384M 61.389M -5.774M 141.152M 139.491M 91.062M 96.116M 34.892M 18.203M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 199.48 184.6 236.4 217.9 376.78 249.86 152.76 113.18 109.45 76.19 80.39 63.64 53.04 37.47 27.25 35.63 36.56 55.13 65.92 43.51 — — — — — —
Price performance 12m 0.08 -0.22 0.08 -0.42 0.51 0.64 0.35 0.03 0.44 -0.05 0.26 0.2 0.42 0.38 -0.24 -0.03 -0.34 -0.16 0.51 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 364M 430M 472M 514M 618M 643M 752M 780M 721M 709M
↳ YoY growth +34.8% +18.1% +9.8% +8.8% +20.2% +4.1% +17.0% +3.7% -7.6% -1.7%
↳ 5y CAGR +14.5% +16.2% +16.4% +14.8% +18.0% +12.0% +11.8% +10.6% +7.0% +2.8%
Borrowings, current (USD) 24.6M 28.5M 28.2M 35.5M 47.2M 101,000 1.35M 3.17M 155,000 166,000
Borrowings, non-current (USD) 1.19B 1.09B 1.63B 1.85B 1.93B 2.66B 2.71B 2.65B 2.24B 2.14B
Lease liabilities (USD) — — 112M 167M 209M 313M 467M 503M 566M 520M
Cash and deposits (USD) 118M 164M 195M 238M 228M 241M 234M 277M 195M 214M
Intangible assets (USD) 394M 370M 611M 689M 788M 1.06B 955M 864M 723M 340M
Right-of-use assets (USD) — — 134M 140M 178M 293M 392M 394M 412M 361M
Net debt (borrowings + leases - cash) (USD) 1.1B 957M 1.46B 1.81B 1.96B 2.74B 2.94B 2.88B 2.61B 2.44B
Cash flow detail
Operating cash flow (USD) 300M 318M 441M 481M 547M 761M 620M 684M 735M 738M
Purchases of property, plant and equipment (USD) -55.3M -82.4M -140M -141M -167M -229M -325M -319M -233M -219M
Change in receivables (cash effect) (USD) -52.8M -48.3M -21.2M -8.32M -85.6M -26.6M -151M -33.4M 21.6M 35.7M
Change in inventories (cash effect) (USD) -4.02M -17.8M -13.3M -21.4M -18.4M -25.2M -78.5M -62.3M 16.8M -48.8M
Change in payables (cash effect) (USD) 22.1M 34,000 -12.7M 29.8M 748,000 44.9M -2.65M -20.4M -14.3M 2.87M
Share buybacks (cash effect) (USD) -12.3M -107M -13.8M -18.1M -24M -40.7M -38.7M -24.2M -119M -361M
Interest paid (cash effect) (USD) -22.8M -27.4M -47.5M -67.8M -72.5M -70.8M -101M -132M -123M -102M
Income taxes paid (cash effect) (USD) -42.9M -60.4M -67.6M -54.1M -60.1M -75.4M -75.9M -90.4M -126M -120M
Share-based compensation (USD) 43.6M 44M 47.3M 57.3M 56.3M 71.5M 73.6M 72M 69.9M 71.1M
Operating cash flow before change in receivables (USD) 353M 366M 462M 489M 632M 787M 770M 717M 713M 702M
Free cash flow (OCF - PPE - intangibles) (USD) 245M 236M 301M 340M 380M 532M 295M 365M 502M 518M
Income detail
Total comprehensive income (USD) 36.5M 236M 203M 249M 406M 374M 392M 545M -98.5M 4.56M
Comprehensive income to owners (USD) 36.5M 232M 202M 247M 403M 365M 389M 540M -98.7M 1.22M
Provision for credit losses (USD) — -900,000 2.1M 3M 6.4M 1.7M 6.7M 18.2M 14.8M 6.06M
Credit cost ratio (credit losses / average receivables) (%) — 0.2% 0.5% 0.6% 1.1% 0.3% 1.0% 2.4% 2.0% 0.8%
Reported Feb 14, 2017 Feb 13, 2018 May 7, 2019 Feb 11, 2020 Feb 17, 2021 Feb 16, 2022 Feb 22, 2023 Feb 14, 2024 Feb 19, 2025 Feb 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

– Strengthens Charles River's Bioanalysis and DMPK Capabilities

to Support Clients Across the Drug Development Lifecycle –

– Advances Pathway to Purpose Strategy and

Enhances Long-Term Growth and Value Creation –

WILMINGTON, MA, November 9, 2026 – Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has entered into definitive agreements to acquire Frontage Holdings Corporation’s bioanalysis and DMPK operations in Exton, Pennsylvania for approximately $470 million in cash, subject to customary closing adjustments. In addition to the initial purchase price, the transaction includes additional payments of up to $75 million, contingent on future performance of the acquired businesses. The transaction is expected to close during the first half of 2027, subject to required shareholder and regulatory approvals, and other customary closing conditions.

Birgit Girshick, Chief Executive Officer, commented, “The planned acquisition accelerates our strategy to expand our bioanalysis capabilities and enhance our offering in an attractive, high-growth market.

Download PDF 497.7 KB

WILMINGTON, Mass.--(BUSINESS WIRE)--Nov. 4, 2026-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter ended September 26, 2026.

Key Highlights

  • Reports third-quarter revenue of $982.7 million, GAAP earnings per share of $6.86, and non-GAAP earnings per share of $3.09.

  • Organic revenue growth of 4.7%, outperforming the Company's prior outlook and representing a return to organic revenue growth for the second consecutive quarter.

  • Operating margin increased year-over-year, with non-GAAP operating margin increasing 330 basis points to 23.0% and GAAP operating margin increasing 730 basis points to 20.6%.

  • Non-GAAP earnings per share increased 27.2% year-over-year.

  • Increases 2026 guidance for revenue and non-GAAP earnings per share.

  • Organic revenue guidance increasing by 100 basis points and non-GAAP earnings per share guidance increasing by $0.15 at midpoint.

  • Guidance increases primarily driven by third-quarter outperformance, led by a better-than-expected performance in the DSA segment and a lower tax rate.

  • Charles River unveiled its Pathway to Purpose strategic vision and Create the Future™ initiative at its 2026 Investor Day, outlining initiatives designed to enhance operational excellence, strengthen scientific leadership, and drive long-term value creation.

  • The Company advanced modernization efforts through the implementation of its Endosafe® Cartridge Technology Automated Manufacturing Suite, which utilizes a fully automated production suite to increase production capacity and strengthen manufacturing controls and digital traceability. In addition, the Company partnered with Autolomous to launch Apollo Orchestrate™, a new capability within Charles River's Apollo® platform to digitize and transform laboratory workflows, increase efficiency, and provide greater transparency and connectivity with clients.

  • Charles River has also taken steps to continue to strengthen its scientific capabilities. It recently announced an industry collaboration with the U.S. Food and Drug Administration (FDA) to validate preclinical screening tools to quantify and rank the abuse potential of new drugs.

  • To further advance its Alternative Methods Advancement Project™ (AMAP™) initiative, the Company introduced a new, rapid cell banking program designed to significantly accelerate product release timelines in its Biologics Testing Solutions business by incorporating in vitro next-generation sequencing capabilities into the cell bank production process. In addition, its Virtual Control Group (VCG) database and methodology will be used in an upcoming Good Laboratory Practice (GLP)-compliant safety assessment study for Ipsen.

Third-Quarter Results

Revenue was $982.7 million, a decrease of 2.2% from $1,004.9 million in the third quarter of 2025, primarily driven by the impact of the May 2026 divestitures. On an organic basis, revenue increased 4.7%, driven by revenue growth in the Manufacturing Solutions (Manufacturing) and Discovery and Safety Assessment (DSA) segments. Organic revenue growth excludes the effect of acquisitions, divestitures, and foreign currency translation.

In the third quarter of 2026, the GAAP operating margin was 20.6%, compared to 13.3% in the third quarter of 2025, driven primarily by a benefit of $44.6 million in the DSA segment from the reversal of acquired non-income tax reserves following newly enacted tax legislation and completion of certain tax requirements in a foreign jurisdiction. The GAAP net income available to common shareholders for the third quarter of 2026 was $333.1 million, or $6.86 per diluted share, compared to GAAP net income of $54.4 million, or $1.10 per diluted share for the same period in 2025. The GAAP net income and earnings per share increases included a benefit totaling $245.6 million, or $5.06 per share, associated with the reversal of acquired tax reserves following newly enacted tax legislation and completion of certain tax requirements in a foreign jurisdiction.

On a non-GAAP basis, the third-quarter operating margin increased to 23.0% from 19.7% in the third quarter of 2025, primarily as a result of the benefit of the CDMO divestiture and operating leverage from higher sales volume for safety assessment services. Non-GAAP net income was $150.1 million for the third quarter of 2026, an increase of 24.8% from $120.3 million for the same period in 2025. Third-quarter diluted earnings per share on a non-GAAP basis were $3.09, an increase of 27.2% from $2.43 per share in the third quarter of 2025. The non-GAAP net income and earnings per share increases were driven primarily by the higher operating margin and a lower tax rate.

Birgit Girshick, Chief Executive Officer, said, “In the third quarter, we were encouraged by the continued strength of the biopharmaceutical demand environment and that was reflected in our financial results. Revenue and earnings per share outperformed our prior expectations, DSA net bookings and proposals continued to show robust, year-over-year increases, and we continued to make meaningful progress towards our strategy and long-term financial targets. We see significant opportunities to continue to strengthen Charles River’s position as a leading scientific partner for regulated testing across the drug development continuum. Through our Pathway to Purpose strategy, we are building a more agile, client-centric organization that will deepen client relationships, expand engagement across our portfolio, and increase our share of R&D spend as demand trends continue to improve."

Third-Quarter Segment Results

Discovery and Safety Assessment (DSA)

Revenue for the DSA segment was $596.3 million in the third quarter of 2026, a decrease of 0.7% from $600.7 million in the third quarter of 2025, primarily driven by the divestiture of certain European Discovery Services sites. Organic revenue increased by 5.9%, driven primarily by higher study volume for regulated safety assessment services.

In the third quarter of 2026, the DSA segment’s GAAP operating margin increased to 28.9% from 20.5% in the third quarter of 2025. The increase was primarily driven by the reversal of acquired non-income tax reserves. On a non-GAAP basis, the operating margin increased to 26.8% from 25.4% in the third quarter of 2025. The non-GAAP operating margin increase was primarily driven by operating leverage from higher study volume for regulated safety assessment services, as well as lower sourcing costs for large research models.

Manufacturing Solutions (Manufacturing)

Revenue for the Manufacturing segment was $178.9 million in the third quarter of 2026, a decrease of 6.2% from $190.7 million in the third quarter of 2025, primarily driven by the CDMO divestiture. Organic revenue increased 7.4%, driven by strong demand in both the Biologics Testing Solutions and Microbial Solutions businesses.

The Manufacturing segment’s GAAP operating margin was 35.7%, compared to 20.9% in the third quarter of 2025. On a non-GAAP basis, the operating margin increased to 38.6% from 26.7% in the third quarter of 2025. The GAAP and non-GAAP increases were driven primarily by the benefit of the CDMO divestiture.

Research Models and Services (RMS)

Revenue for the RMS segment was $207.5 million in the third quarter of 2026, a decrease of 2.8% from $213.5 million in the third quarter of 2025, primarily driven by the Cell Solutions divestiture. Organic revenue decreased by 0.6%, due primarily to lower revenue for small research models in North America and for large research models. The decline was partially offset by higher revenue for small research models in China and for research model services, particularly the Insourcing Solutions business.

In the third quarter of 2026, the RMS segment’s GAAP operating margin increased to 19.9% from 16.2% in the third quarter of 2025, primarily due to lower costs related to the Cell Solutions divestiture and restructuring initiatives. On a non-GAAP basis, the operating margin decreased to 24.4% from 25.0%. The non-GAAP operating margin decrease was primarily driven by the impact of an unfavorable revenue mix, both geographically and related to large research models.

2026 Guidance Update

The Company is increasing its 2026 revenue and earnings per share guidance, which was last updated on August 5, 2026. This increase primarily reflects the third-quarter outperformance, which was principally driven by the better-than-expected performance in the DSA segment and a lower tax rate. On a GAAP basis, the Company is also increasing its earnings per share guidance, due primarily to the third-quarter benefit associated with the reversal of acquired tax reserves.

The Company’s 2026 guidance for revenue and earnings per share is as follows:

| 2026 GUIDANCE | CURRENT | PRIOR |

| Revenue growth/(decrease), reported | (2.0)% - (1.5)% | (3.5)% - (2.5)% |

| Less: Contribution from acquisitions | 0.0% - (0.5)% | 0.0% - (0.5)% |

| Add: Impact from divestitures | ~4.5% | ~4.5% |

| Less: Favorable impact of foreign exchange | (0.5)% - (1.0)% | (0.5)% - (1.0)% |

| Revenue growth/(decrease), organic (1) | At least +1.5% | 0.0% - 1.0% |

| GAAP EPS estimate | $8.15 – $8.35 | $3.05 – $3.35 |

| Acquisition-related amortization (2) | ~$2.10 | ~$2.30 |

| Acquisition- and divestiture-related costs (3) | ~$4.70 | ~$4.75 |

| Reversal of acquired tax reserves (4) | ($5.03) | -- |

| Costs associated with restructuring and efficiency initiatives (5) | ~$1.50 | ~$1.20 |

| Other, net (6) | ($0.03) | ($0.17) |

| Non-GAAP EPS estimate | $11.35 – $11.55 | $11.15 – $11.45 |

| | | |

| Footnotes to Guidance Table: |

| (1) Organic revenue growth is defined as reported revenue growth adjusted for completed acquisitions and divestitures (including the CDMO and Cell Solutions businesses, as well as certain European Discovery Services sites), as well as foreign currency translation. |

| (2) These adjustments primarily include amortization related to intangible assets, as well as the purchase accounting step-up on inventory and certain long-term biological assets. |

| (3) These adjustments include costs related to the evaluation and integration of acquisitions and divestitures, as well as a net loss on divestitures and other transaction-related tax adjustments. |

| (4) This adjustment is related to the third-quarter benefit associated with the reversal of acquired tax reserves following newly enacted tax legislation and completion of certain tax requirements in a foreign jurisdiction. |

| (5) These adjustments primarily include site consolidation (including site transition costs), severance, impairment, third-party consulting and professional services, and other costs related to the Company’s restructuring actions and efficiency initiatives. These adjustments also include gains and/or losses on the sale of certain assets and real estate. |

| (6) These adjustments primarily include: (i) certain venture capital and other strategic investment losses/(gains), net. This item only includes recognized gains or losses on certain investments. The Company does not forecast the future performance of these investments; and (ii) reductions to a previous $27 million inventory charge associated with a non-human primate (NHP) supply matter. As a result of the resolution of the U.S. government investigations during fiscal year 2025, certain NHPs were subsequently utilized. |

Webcast

Charles River has scheduled a live webcast on Wednesday, November 4, 2026, at 9:00 a.m. ET to discuss matters relating to this press release. To participate, please go to ir.criver.com and select the webcast link. You can also find the associated slide presentation and reconciliations of GAAP financial measures to non-GAAP financial measures on the website.

Non-GAAP Reconciliations

The Company reports non-GAAP results in this press release, which exclude often-one-time charges and other items that are outside of normal operations. A reconciliation of GAAP to non-GAAP results is provided in the schedules at the end of this press release.

Use of Non-GAAP Financial Measures

This press release contains non-GAAP financial measures, such as non-GAAP earnings per share, non-GAAP operating income, non-GAAP operating margin, and non-GAAP net income. Non-GAAP financial measures exclude, but are not limited to, the amortization of intangible assets and the purchase accounting step-up adjustment on inventory and certain long term biological assets, and other charges and adjustments related to our acquisitions and divestitures, including expenses associated with evaluating and integrating acquisitions and divestitures, including advisory fees, certain transition costs, and certain other transaction-related costs, as well as fair value adjustments associated with contingent consideration; charges, gains, and losses attributable to businesses or properties we plan to close, consolidate, or divest, including the divestitures of our CDMO and Cell Solutions businesses, the sale of certain of our European Discovery Services sites, and the sale of certain assets including real estate; severance and other costs associated with our restructuring initiatives; investment gains or losses associated with our venture capital and certain other strategic equity investments; certain legal costs and adjustments related to an NHP inventory charge in our DSA segment related to now concluded U.S. government investigations into the NHP supply chain; legal and advisory costs related to entering into a Cooperation Agreement with a shareholder; tax effect of all of the aforementioned matters; and adjustments related to the derecognition of certain deferred tax assets due to the CDMO Gene Therapy intangible asset impairment charge, the recognition of deferred tax assets expected to be utilized as a result of changes to the Company's international financing structure, the revaluation of deferred tax liabilities as a result of foreign tax legislation, and the tax benefit recognized as a result of the changes in tax law enacted in a foreign jurisdiction. This press release also refers to our revenue on both a GAAP and non-GAAP basis: on a non-GAAP basis, we define “organic revenue growth” as reported revenue growth adjusted for foreign currency translation, acquisitions, and divestitures. We exclude these items from the non-GAAP financial measures because they are outside our normal operations. There are limitations in using non-GAAP financial measures, as they are not presented in accordance with generally accepted accounting principles, and may be different than non-GAAP financial measures used by other companies. In particular, we believe that the inclusion of supplementary non-GAAP financial measures in this press release helps investors to gain a meaningful understanding of our core operating results and future prospects without the effect of these often-one-time charges, and is consistent with how management measures and forecasts the Company's performance, especially when comparing such results to prior periods or forecasts. We believe that the financial impact of our acquisitions and divestitures (and in certain cases, the evaluation of such acquisitions and divestitures, whether or not ultimately consummated) is often large relative to our overall financial performance, which can adversely affect the comparability of our results on a period-to-period basis. In addition, certain activities and their underlying associated costs, such as business acquisitions, generally occur periodically but on an unpredictable basis. We calculate non-GAAP integration costs to include third-party integration costs incurred post-acquisition. Presenting revenue on an organic basis allows investors to measure our revenue growth exclusive of acquisitions, divestitures, and foreign currency exchange fluctuations more clearly. Non-GAAP results also allow investors to compare the Company’s operations against the financial results of other companies in the industry who similarly provide non-GAAP results. The non-GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations presented in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. Reconciliations of the non-GAAP financial measures used in this press release to the most directly comparable GAAP financial measures are set forth in this press release, and can also be found on the Company’s website at ir.criver.com.

Caution Concerning Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “will,” “would,” “may,” “estimate,” “plan,” “outlook,” and “project,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding: the projected and/or anticipated future financial performance of Charles River and our specific businesses, including as delineated in our forward-looking guidance, and particularly our expectations with respect to revenue, the impact of foreign exchange, interest rates, and enhanced efficiency initiatives, including our Create the Future initiative; our expectations with respect to our ability to gain market share; our ability to create long-term value for our shareholders and successfully execute on our strategic initiatives, including our Pathway to Purpose strategic vision, and the impact and results of such initiatives; the Company’s plans or prospects, expectations and long-term goals associated with our business; earnings per share; operating margin; client demand, particularly the future demand for drug discovery and development products and services, including our expectations for future revenue trends; our expectations with respect to booking trends and the impacts thereof; our expectations with respect to pricing of our products and services; our expectations with respect to future tax rates and the impact of such tax rates on our business; our expectations with respect to the impact of acquisitions and divestitures, including the acquisition of the assets of K.F. (Cambodia) Ltd. and of PathoQuest SAS, the divestitures of the Company's CDMO and Cell Solutions businesses, the sale of certain of our European Discovery Services sites, and the sale of certain assets including real estate; our service offerings, client perception, strategic relationships, revenue, revenue growth rates, revenue growth drivers, and earnings; the development and performance of our services and products, including our investments in our portfolio; market and industry conditions including the outsourcing of services and identification of spending trends by our clients and funding available to them; ability to gain market share and capitalize on business and growth opportunities; the impact of our restructuring initiatives, including annualized savings; and the impact of our stock repurchase authorization. Forward-looking statements are based on Charles River’s current expectations and beliefs, speak only as of the date of this press release, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: the impact of NHP supply constraints; changes and uncertainties in the global economy and financial markets, including disruptions in the global economy caused by geopolitical conflicts; the ability to successfully integrate businesses we acquire, and risks and uncertainties associated with businesses that we acquire; the timing and magnitude of our share repurchases; negative trends in research and development spending, negative trends in the level of outsourced services, or other cost reduction actions by our clients; the ability to convert backlog to revenue; demand and booking trends; special interest groups; contaminations; industry trends; new displacement technologies; USDA and FDA regulations; changes in law; continued availability of products and supplies; the impact of unauthorized access into our information systems; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in tax regulation and laws; changes in generally accepted accounting principles; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 18, 2026, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River. Charles River assumes no obligation and expressly disclaims any duty to update information contained in this press release except as required by law.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. |

| | | | | | | | | |

| SCHEDULE 1 |

| CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) |

| (in thousands, except for per share data) |

| | | | | | | | | |

| | | Three Months Ended | | Nine Months Ended |

| | | September 26, 2026 | | September 27, 2025 | | September 26, 2026 | | September 27, 2025 |

| | | | | | | | | |

| Service revenue | $ | 780,341 | | | $ | 808,042 | | | $ | 2,386,780 | | | $ | 2,446,801 | |

| Product revenue | | 202,391 | | | | 196,810 | | | | 595,860 | | | | 574,354 | |

| Total revenue | | 982,732 | | | | 1,004,852 | | | | 2,982,640 | | | | 3,021,155 | |

| Costs and expenses: | | | | | | | |

| Cost of services provided (excluding amortization of intangible assets) | | 522,836 | | | | 572,635 | | | | 1,683,750 | | | | 1,734,939 | |

| Cost of products sold (excluding amortization of intangible assets) | | 102,026 | | | | 93,425 | | | | 282,982 | | | | 272,625 | |

| Selling, general and administrative | | 140,591 | | | | 177,589 | | | | 528,910 | | | | 546,937 | |

| Amortization of intangible assets | | 14,641 | | | | 27,404 | | | | 44,575 | | | | 158,052 | |

| Operating income | | 202,638 | | | | 133,799 | | | | 442,423 | | | | 308,602 | |

| Other income (expense): | | | | | | | |

| Interest income | | 958 | | | | 1,422 | | | | 3,023 | | | | 3,923 | |

| Interest expense | | (28,525 | ) | | | (25,403 | ) | | | (85,607 | ) | | | (83,254 | ) |

| Other expense, net | | (4,414 | ) | | | (22,618 | ) | | | (165,954 | ) | | | (34,675 | ) |

| Income before income taxes | | 170,657 | | | | 87,200 | | | | 193,885 | | | | 194,596 | |

| Provision (benefit) for income taxes | | (163,787 | ) | | | 31,644 | | | | (124,997 | ) | | | 60,469 | |

| Net income | | 334,444 | | | | 55,556 | | | | 318,882 | | | | 134,127 | |

| Less: Net income attributable to noncontrolling interests | | 1,377 | | | | 1,134 | | | | 2,140 | | | | 1,910 | |

| Net income attributable to common shareholders | $ | 333,067 | | | $ | 54,422 | | | $ | 316,742 | | | $ | 132,217 | |

| | | | | | | | |

| Earnings per common share | | | | | | | |

| Basic | $ | 6.97 | | | $ | 1.11 | | | $ | 6.56 | | | $ | 2.66 | |

| Diluted | $ | 6.86 | | | $ | 1.10 | | | $ | 6.48 | | | $ | 2.65 | |

| | | | | | | | | |

| Weighted-average number of common shares outstanding | | | | | | | |

| Basic | | 47,803 | | | | 49,213 | | | | 48,258 | | | | 49,680 | |

| Diluted | | 48,584 | | | | 49,426 | | | | 48,899 | | | | 49,866 | |

| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. |

| |

| SCHEDULE 2 |

| CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) |

| (in thousands, except per share amounts) |

| | | | |

| | September 26, 2026 | | December 27, 2025 |

| Assets | | | |

| Current assets: | | | |

| Cash and cash equivalents | $ | 200,381 | | | $ | 213,770 | |

| Trade receivables and contract assets, net of allowances for credit losses of $10,511 and $10,463, respectively | | 735,305 | | | | 708,856 | |

| Inventories | | 319,638 | | | | 299,103 | |

| Prepaid assets | | 97,265 | | | | 96,108 | |

| Other current assets | | 182,439 | | | | 129,212 | |

| Total current assets | | 1,535,028 | | | | 1,447,049 | |

| Property, plant and equipment, net | | 1,497,335 | | | | 1,655,219 | |

| Venture capital and strategic equity investments | | 194,521 | | | | 206,972 | |

| Operating lease right-of-use assets, net | | 332,330 | | | | 361,415 | |

| Goodwill | | 3,084,112 | | | | 2,764,253 | |

| Intangible assets, net | | 238,662 | | | | 339,995 | |

| Deferred tax assets | | 67,467 | | | | 67,334 | |

| Other assets | | 502,052 | | | | 293,185 | |

| Total assets | $ | 7,451,507 | | | $ | 7,135,422 | |

| | | | |

| Liabilities, Redeemable Noncontrolling Interests and Equity | | | |

| Current liabilities: | | | |

| Accounts payable | $ | 144,507 | | | $ | 148,800 | |

| Accrued compensation | | 225,937 | | | | 268,854 | |

| Deferred revenue | | 204,204 | | | | 210,418 | |

| Accrued liabilities | | 285,737 | | | | 270,085 | |

| Other current liabilities | | 228,873 | | | | 222,158 | |

| Total current liabilities | | 1,089,258 | | | | 1,120,315 | |

| Long-term debt, net and finance leases | | 2,443,461 | | | | 2,136,360 | |

| Operating lease right-of-use liabilities | | 405,351 | | | | 434,048 | |

| Deferred tax liabilities | | 81,815 | | | | 95,203 | |

| Other long-term liabilities | | 156,356 | | | | 138,302 | |

| Total liabilities | | 4,176,241 | | | | 3,924,228 | |

| Redeemable noncontrolling interests | | 43,173 | | | | 41,263 | |

| Equity: | | | |

| Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding | | — | | | | — | |

| Common stock, $0.01 par value; 120,000 shares authorized; 49,699 shares issued and 47,876 shares outstanding as of September 26, 2026, and 49,217 shares issued and outstanding as of December 27, 2025 | | 497 | | | | 492 | |

| Additional paid-in capital | | 2,035,124 | | | | 1,947,301 | |

| Retained earnings | | 1,705,362 | | | | 1,388,620 | |

| Treasury stock, at cost, 1,823 and zero shares, as of September 26, 2026 and December 27, 2025, respectively | | (323,281 | ) | | | — | |

| Accumulated other comprehensive loss | | (190,691 | ) | | | (171,783 | ) |

| Total Charles River Laboratories International, Inc. equity | | 3,227,011 | | | | 3,164,630 | |

| Nonredeemable noncontrolling interest | | 5,082 | | | | 5,301 | |

| Total equity | | 3,232,093 | | | | 3,169,931 | |

| Total liabilities, redeemable noncontrolling interests and equity | $ | 7,451,507 | | | $ | 7,135,422 | |

| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. |

| |

| SCHEDULE 3 |

| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) |

| (in thousands) |

| | Nine Months Ended |

| | September 26, 2026 | | September 27, 2025 |

| Cash flows relating to operating activities | | | |

| Net income | $ | 318,882 | | | $ | 134,127 | |

| Adjustments to reconcile net income to net cash provided by operating activities: | | | |

| Depreciation and amortization | | 206,701 | | | | 325,035 | |

| Long-lived asset impairments | | 27,171 | | | | 36,185 | |

| Stock-based compensation | | 62,929 | | | | 53,451 | |

| Deferred income taxes | | (4,089 | ) | | | (15,122 | ) |

| Reversal of an unrecognized tax benefit reserve and related interest and penalties | | (245,638 | ) | | | — | |

| Write down of inventories | | 4,033 | | | | 10,697 | |

| (Gains) losses and impairments on venture capital and strategic equity investments, net | | (4,897 | ) | | | 33,955 | |

| (Gain) loss on sale of assets | | (37,776 | ) | | | 982 | |

| Provision for credit losses | | 1,935 | | | | 4,559 | |

| (Gain) loss on divestitures, net | | 180,300 | | | | (3,376 | ) |

| Other, net | | (8,538 | ) | | | 2,324 | |

| Changes in assets and liabilities: | | | |

| Trade receivables and contract assets, net | | (110,271 | ) | | | 8,106 | |

| Inventories | | 64,440 | | | | (45,280 | ) |

| Accounts payable | | 25,601 | | | | 40,747 | |

| Accrued compensation | | (26,898 | ) | | | 81,870 | |

| Deferred revenue | | 6,227 | | | | (12,319 | ) |

| Customer contract deposits | | 12,681 | | | | (533 | ) |

| Other assets and liabilities, net | | 2,094 | | | | (65,282 | ) |

| Net cash provided by operating activities | | 474,887 | | | | 590,126 | |

| Cash flows relating to investing activities | | | |

| Acquisition of businesses and assets, net of cash acquired | | (467,254 | ) | | | — | |

| Capital expenditures | | (133,823 | ) | | | (130,202 | ) |

| Purchases of investments and contributions to venture capital investments | | (14,718 | ) | | | (12,544 | ) |

| Proceeds from sale of investments | | 18,876 | | | | 5,637 | |

| Proceeds from surrender of life insurance policies | | 58,127 | | | | — | |

| Proceeds from sale of businesses and assets, net | | 176,563 | | | | 17,441 | |

| Other, net | | (7,292 | ) | | | 3,154 | |

| Net cash used in investing activities | | (369,521 | ) | | | (116,514 | ) |

| Cash flows relating to financing activities | | | |

| Proceeds from long-term debt and revolving credit facility | | 1,420,223 | | | | 1,070,861 | |

| Payments on long-term debt, revolving credit facility, and finance lease obligations | | (1,081,266 | ) | | | (1,141,500 | ) |

| Proceeds from exercises of stock options | | 29,733 | | | | 3 | |

| Purchase of treasury stock | | (324,105 | ) | | | (360,577 | ) |

| Payment of contingent consideration and deferred acquisition consideration | | (111,394 | ) | | | (21,822 | ) |

| Purchase of remaining equity interests of other redeemable noncontrolling interest | | — | | | | (19,140 | ) |

| Other, net | | (4,274 | ) | | | (12,687 | ) |

| Net cash used in financing activities | | (71,083 | ) | | | (484,862 | ) |

| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | | (1,199 | ) | | | 14,900 | |

| Net change in cash, cash equivalents, and restricted cash | | 33,084 | | | | 3,650 | |

| Cash, cash equivalents, and restricted cash, beginning of period | | 215,997 | | | | 205,570 | |

| Cash, cash equivalents, and restricted cash, end of period | $ | 249,081 | | | $ | 209,220 | |

| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. |

| | | | | | | | | | |

| SCHEDULE 4 |

| RECONCILIATION OF GAAP TO NON-GAAP |

| SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)(1) |

| (in thousands, except percentages) |

| | | | | | | | | | |

| | | | Three Months Ended | | Nine Months Ended |

| | | | September 26, 2026 | | September 27, 2025 | | September 26, 2026 | | September 27, 2025 |

| Discovery and Safety Assessment | | | | | | | | |

| | Revenue | | $ | 596,322 | | | $ | 600,685 | | | $ | 1,799,752 | | | $ | 1,811,323 | |

| | Operating income | | | 172,376 | | | | 123,153 | | | | 400,650 | | | | 339,886 | |

| | Operating income as a % of revenue | | | 28.9 | % | | | 20.5 | % | | | 22.3 | % | | | 18.8 | % |

| | Add back: | | | | | | | | |

| | Amortization related to acquisitions | | | 22,388 | | | | 19,198 | | | | 57,671 | | | | 55,581 | |

| | Acquisition, integration, and divestiture-related adjustments (2) | | | (43,603 | ) | | | 2,407 | | | | (35,368 | ) | | | 4,755 | |

| | Severance | | | 4,487 | | | | (148 | ) | | | 8,193 | | | | 5,068 | |

| | Asset impairment | | | — | | | | 693 | | | | 3,261 | | | | 22,390 | |

| | Cost savings and efficiency initiatives (3) | | | 5,173 | | | | 3,985 | | | | 13,952 | | | | 10,690 | |

| | Third-party legal and advisory costs and certain related items (4) | | | (1,272 | ) | | | 3,242 | | | | (8,414 | ) | | | 25,029 | |

| | Total non-GAAP adjustments to operating income | | $ | (12,827 | ) | | $ | 29,377 | | | $ | 39,295 | | | $ | 123,513 | |

| | Operating income, excluding non-GAAP adjustments | | $ | 159,549 | | | $ | 152,530 | | | $ | 439,945 | | | $ | 463,399 | |

| | Non-GAAP operating income as a % of revenue | | | 26.8 | % | | | 25.4 | % | | | 24.4 | % | | | 25.6 | % |

| | | | | | | | | | |

| | Depreciation and amortization | | $ | 45,281 | | | $ | 44,001 | | | $ | 126,828 | | | $ | 128,660 | |

| | Capital expenditures | | $ | 30,048 | | | $ | 25,709 | | | $ | 87,990 | | | $ | 78,730 | |

| | | | | | | | | | |

| Manufacturing Solutions | | | | | | | | |

| | Revenue | | $ | 178,878 | | | $ | 190,693 | | | $ | 557,514 | | | $ | 570,014 | |

| | Operating income | | | 63,835 | | | | 39,926 | | | | 176,280 | | | | 43,367 | |

| | Operating income as a % of revenue | | | 35.7 | % | | | 20.9 | % | | | 31.6 | % | | | 7.6 | % |

| | Add back: | | | | | | | | |

| | Amortization related to acquisitions (5) | | | 2,145 | | | | 8,265 | | | | 6,151 | | | | 100,675 | |

| | Acquisition, integration, and divestiture-related adjustments (2) | | | 1,431 | | | | — | | | | 4,195 | | | | — | |

| | Severance | | | 1,348 | | | | 1,281 | | | | 806 | | | | 3,102 | |

| | Asset impairment | | | 316 | | | | 91 | | | | 567 | | | | 6,449 | |

| | Cost savings and efficiency initiatives (3) | | | — | | | | 1,263 | | | | 1,511 | | | | 4,239 | |

| | Total non-GAAP adjustments to operating income | | $ | 5,240 | | | $ | 10,900 | | | $ | 13,230 | | | $ | 114,465 | |

| | Operating income, excluding non-GAAP adjustments | | $ | 69,075 | | | $ | 50,826 | | | $ | 189,510 | | | $ | 157,832 | |

| | Non-GAAP operating income as a % of revenue | | | 38.6 | % | | | 26.7 | % | | | 34.0 | % | | | 27.7 | % |

| | | | | | | | | | |

| | Depreciation and amortization | | $ | 7,784 | | | $ | 17,377 | | | $ | 23,572 | | | $ | 127,343 | |

| | Capital expenditures | | $ | 6,839 | | | $ | 5,191 | | | $ | 18,747 | | | $ | 33,631 | |

| | | | | | | | | | |

| Research Models and Services | | | | | | | | |

| | Revenue | | $ | 207,532 | | | $ | 213,474 | | | $ | 625,374 | | | $ | 639,818 | |

| | Operating income | | | 41,240 | | | | 34,553 | | | | 127,290 | | | | 113,944 | |

| | Operating income as a % of revenue | | | 19.9 | % | | | 16.2 | % | | | 20.4 | % | | | 17.8 | % |

| | Add back: | | | | | | | | |

| | Amortization related to acquisitions | | | 7,063 | | | | 12,905 | | | | 21,601 | | | | 36,266 | |

| | Acquisition, integration, and divestiture-related adjustments (2) | | | — | | | | — | | | | 67 | | | | 14 | |

| | Severance | | | 817 | | | | 136 | | | | 1,453 | | | | 3,664 | |

| | Asset impairment | | | — | | | | 4,635 | | | | 22,031 | | | | 7,458 | |

| | Cost savings and efficiency initiatives (3) | | | 1,598 | | | | 1,053 | | | | (18,935 | ) | | | 3,545 | |

| | Total non-GAAP adjustments to operating income | | $ | 9,478 | | | $ | 18,729 | | | $ | 26,217 | | | $ | 50,947 | |

| | Operating income, excluding non-GAAP adjustments | | $ | 50,718 | | | $ | 53,282 | | | $ | 153,507 | | | $ | 164,891 | |

| | Non-GAAP operating income as a % of revenue | | | 24.4 | % | | | 25.0 | % | | | 24.5 | % | | | 25.8 | % |

| | | | | | | | | | |

| | Depreciation and amortization | | $ | 16,145 | | | $ | 21,939 | | | $ | 48,018 | | | $ | 63,410 | |

| | Capital expenditures | | $ | 9,411 | | | $ | 3,173 | | | $ | 25,968 | | | $ | 14,099 | |

| | | | | | | | | | |

| Unallocated Corporate Overhead | | $ | (74,813 | ) | | $ | (63,833 | ) | | $ | (261,797 | ) | | $ | (188,595 | ) |

| | Add back: | | | | | | | | |

| | Acquisition, integration, and divestiture-related adjustments (2) | | | 10,258 | | | | 772 | | | | 45,020 | | | | 3,663 | |

| | Severance | | | 2,467 | | | | 3,527 | | | | 7,138 | | | | 5,103 | |

| | Asset impairment | | | 422 | | | | — | | | | 965 | | | | 184 | |

| | Cost savings and efficiency initiatives (3) | | | 8,106 | | | | 767 | | | | 19,803 | | | | 1,436 | |

| | Third-party legal and advisory costs (4) | | | — | | | | (146 | ) | | | — | | | | 6,230 | |

| | Total non-GAAP adjustments to operating expense | | $ | 21,253 | | | $ | 4,920 | | | $ | 72,926 | | | $ | 16,616 | |

| | Unallocated corporate overhead, excluding non-GAAP adjustments | | $ | (53,560 | ) | | $ | (58,913 | ) | | $ | (188,871 | ) | | $ | (171,979 | ) |

| | | | | | | | | | |

| Total | | | | | | | | |

| | Revenue | | $ | 982,732 | | | $ | 1,004,852 | | | $ | 2,982,640 | | | $ | 3,021,155 | |

| | Operating income | | | 202,638 | | | | 133,799 | | | | 442,423 | | | | 308,602 | |

| | Operating income as a % of revenue | | | 20.6 | % | | | 13.3 | % | | | 14.8 | % | | | 10.2 | % |

| | Add back: | | | | | | | | |

| | Amortization related to acquisitions (5) | | | 31,596 | | | | 40,368 | | | | 85,423 | | | | 192,522 | |

| | Acquisition, integration, and divestiture-related adjustments (2) | | | (31,914 | ) | | | 3,179 | | | | 13,914 | | | | 8,432 | |

| | Severance | | | 9,119 | | | | 4,796 | | | | 17,590 | | | | 16,937 | |

| | Asset impairment | | | 738 | | | | 5,419 | | | | 26,824 | | | | 36,481 | |

| | Cost savings and efficiency initiatives (3) | | | 14,877 | | | | 7,068 | | | | 16,331 | | | | 19,910 | |

| | Third-party legal and advisory costs and certain related items (4) | | | (1,272 | ) | | | 3,096 | | | | (8,414 | ) | | | 31,259 | |

| | Total non-GAAP adjustments to operating income | | $ | 23,144 | | | $ | 63,926 | | | $ | 151,668 | | | $ | 305,541 | |

| | Operating income, excluding non-GAAP adjustments | | $ | 225,782 | | | $ | 197,725 | | | $ | 594,091 | | | $ | 614,143 | |

| | Non-GAAP operating income as a % of revenue | | | 23.0 | % | | | 19.7 | % | | | 19.9 | % | | | 20.3 | % |

| | | | | | | | | | |

| | Depreciation and amortization | | $ | 72,260 | | | $ | 85,164 | | | $ | 206,701 | | | $ | 325,035 | |

| | Capital expenditures | | $ | 46,810 | | | $ | 35,580 | | | $ | 133,823 | | | $ | 130,202 | |

| | | | | | | | | | |

| (1) | | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. |

| (2) | | These adjustments are related to the evaluation and integration of acquisitions and divestitures, and primarily include transaction, advisory, certain third-party integration, certain compensation costs, and related costs; as well as fair value adjustments associated with contingent consideration arrangements. For the three and nine months ended September 26, 2026, this amount includes a $44.6 million tax benefit resulting from newly enacted tax legislation and completion of certain tax requirements in a foreign jurisdiction within the Discovery and Safety Assessment reportable segment. |

| (3) | | Cost savings and efficiency initiatives in 2026 primarily include site consolidation charges related to recent site optimization activities, cost of professional services related to certain improvement initiatives, and a pre-tax gain of $38.5 million in connection with the sale of certain assets in Wilmington, Massachusetts. The gain was recognized within the RMS reportable segment and unallocated corporate for $23.2 million and $15.3 million, respectively. |

| (4) | | Within the DSA business, third‑party legal and advisory costs incurred during fiscal 2025 relate to U.S. government investigations into the NHP supply chain, which were concluded in fiscal 2025. Also included within DSA results for fiscal 2026 is the utilization of previously written‑down NHP inventory, resulting in partial reversals of the $27 million inventory charge recorded in fiscal 2024 following the resolution of the matter in fiscal 2025. Within Unallocated Corporate, third-party legal and advisory costs incurred during fiscal 2025 are associated with the execution of the Cooperation Agreement with a shareholder. |

| (5) | | Amortization related to acquisitions for the nine months ended September 27, 2025 includes $71.0 million of accelerated amortization of certain client relationships in the Biologics Solutions reporting unit within the Manufacturing Solutions reportable segment. |

| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. |

| |

| SCHEDULE 5 |

| RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (UNAUDITED)(1) |

| (in thousands, except per share data) |

| | | Three Months Ended | | Nine Months Ended |

| | | September 26, 2026 | | September 27, 2025 | | September 26, 2026 | | September 27, 2025 |

| | | | | | | | | |

| Net income available to Charles River Laboratories International, Inc. common shareholders | $ | 333,067 | | | $ | 54,422 | | | $ | 316,742 | | | $ | 132,217 | |

| Add back: | | | | | | | |

| Non-GAAP adjustments to operating income (2) | | 22,123 | | | | 62,632 | | | | 148,586 | | | | 302,104 | |

| Venture capital and strategic equity investment losses and impairments, net | | 2,231 | | | | 20,201 | | | | (4,636 | ) | | | 31,594 | |

| (Gain) loss on divestitures (3) | | 461 | | | | — | | | | 180,687 | | | | (3,376 | ) |

| Accretion of deferred acquisition consideration (4) | | 1,081 | | | | — | | | | 2,741 | | | | — | |

| Tax effect of non-GAAP adjustments: | | | | | | | |

| Enacted tax law changes | | — | | | | 3,236 | | | | — | | | | 3,236 | |

| Tax impact of divestitures | | — | | | | — | | | | (35,652 | ) | | | — | |

| Interest on acquired uncertain tax positions | | — | | | | — | | | | 11,271 | | | | — | |

| Reversal of an unrecognized tax benefit reserve and related interest and penalties (5) | | (201,057 | ) | | | — | | | | (201,057 | ) | | | — | |

| Tax effect of the remaining non-GAAP adjustments | | (7,778 | ) | | | (20,148 | ) | | | (20,620 | ) | | | (72,330 | ) |

| Net income available to Charles River Laboratories International, Inc. common shareholders, excluding non-GAAP adjustments | $ | 150,128 | | | $ | 120,343 | | | $ | 398,062 | | | $ | 393,445 | |

| | | | | | | | | |

| Weighted average shares outstanding - Basic | | 47,803 | | | | 49,213 | | | | 48,258 | | | | 49,680 | |

| Effect of dilutive securities: | | | | | | | |

| Stock options, restricted stock units and performance share units | | 781 | | | | 213 | | | | 641 | | | | 186 | |

| Weighted average shares outstanding - Diluted | | 48,584 | | | | 49,426 | | | | 48,899 | | | | 49,866 | |

| | | | | | | | | |

| Earnings per share attributable to common shareholders: | | | | | | | |

| Basic | $ | 6.97 | | | $ | 1.11 | | | $ | 6.56 | | | $ | 2.66 | |

| Diluted | $ | 6.86 | | | $ | 1.10 | | | $ | 6.48 | | | $ | 2.65 | |

| | | | | | | | | |

| Basic, excluding non-GAAP adjustments | $ | 3.14 | | | $ | 2.45 | | | $ | 8.25 | | | $ | 7.92 | |

| Diluted, excluding non-GAAP adjustments | $ | 3.09 | | | $ | 2.43 | | | $ | 8.14 | | | $ | 7.89 | |

| | | | | | | | | |

| (1) | | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. |

| (2) | | This amount excludes non-GAAP adjustments attributable to noncontrolling interest holders. |

| (3) | | The amount included in the nine month period ended September 26, 2026 primarily reflects a $181.7 million loss on the CDMO and Cell Solutions Divestiture, net with a $1.4 million gain on the European Discovery Divestiture. The amount included in 2025 relates to a gain on the sale of a DSA site. |

| (4) | | Represents non-cash interest expense recognized from the accretion of deferred purchase consideration associated with the Cambodia NHP Supplier acquisition. |

| (5) | | The amount included in the nine month period ended September 26, 2026 reflects the tax benefit resulting from the reversal of an unrecognized tax benefit reserve following newly enacted tax legislation and completion of certain tax requirements in a foreign jurisdiction. |

| | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. |

| | | | | | | | | | |

| | SCHEDULE 6 |

| | RECONCILIATION OF GAAP REVENUE GROWTH |

| | TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED) (1) |

| | | | | | | | | | |

| | | | | | | | | | |

| Three Months Ended September 26, 2026 | | Total CRL | | DSA Segment | | MS Segment | | RMS Segment |

| | | | | | | | | | |

| Revenue growth, reported | | (2.2 | )% | | (0.7 | )% | | (6.2 | )% | | (2.8 | )% |

| (Increase) decrease due to foreign exchange | | — | % | | 0.2 | % | | 0.2 | % | | (0.7 | )% |

| Contribution from acquisitions (2) | | (0.2 | )% | | — | % | | (0.8 | )% | | — | % |

| Impact of divestitures (3) | | 7.1 | % | | 6.4 | % | | 14.2 | % | | 2.9 | % |

| Non-GAAP revenue growth, organic (4) | | 4.7 | % | | 5.9 | % | | 7.4 | % | | (0.6 | )% |

| | | | | | | | | | |

| Nine Months Ended September 26, 2026 | | Total CRL | | DSA Segment | | MS Segment | | RMS Segment |

| | | | | | | | | | |

| Revenue growth, reported | | (1.3 | )% | | (0.6 | )% | | (2.2 | )% | | (2.3 | )% |

| (Increase) decrease due to foreign exchange | | (1.1 | )% | | (0.8 | )% | | (1.5 | )% | | (1.8 | )% |

| Contribution from acquisitions (2) | | (0.1 | )% | | — | % | | (0.6 | )% | | — | % |

| Impact of divestitures (3) | | 3.5 | % | | 2.9 | % | | 8.1 | % | | 1.6 | % |

| Non-GAAP revenue growth, organic (4) | | 1.0 | % | | 1.5 | % | | 3.8 | % | | (2.5 | )% |

| | | | | | | | | | |

| (1) | | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. |

| (2) | | The contribution from acquisitions reflects only completed acquisitions. |

| (3) | | Impact of divestitures relates to the sale of certain European Discovery Services businesses in May 2026 within the DSA reportable segment as well as the sale of the CDMO and Cell Solutions businesses in May 2026 within the Manufacturing reportable segment and RMS reportable segment, respectively. |

| (4) | | Organic revenue growth is defined as reported revenue growth adjusted for acquisitions, divestitures and foreign exchange. |

View source version on businesswire.com: https://www.businesswire.com/news/home/20261104526679/en/

Investor Contact: Todd Spencer Corporate Vice President, Investor Relations 781.222.6455 [email protected]

Media Contact: Amy Cianciaruso Corporate Senior Vice President, Chief Communications Officer 781.222.6168 [email protected]

Source: Charles River Laboratories International, Inc.

Stock Quote

CRL (common)

Price

$337.52

Change (%)

+24.5 (+7.83%)

Volume

1,063,758

Exchange

NYSE

Data as of 11/06/26 4:10 pm EST Data Provided by Refinitiv. Minimum 15 minutes delayed.

Featured Reports

2025 Annual Report View PDF Print PDF

Charles River Corporate Citizenship Report View PDF Print PDF

Charles River Leverages Virtual Control Groups in GLP Studies Bull 1 Bear 0 Order/contract

Download PDF

Collaboration highlights ongoing commitment to industry modernization and the highest animal welfare standards

WILMINGTON, Mass.--(BUSINESS WIRE)--Oct. 27, 2026-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its Virtual Control Group (VCG) database and methodology, aimed at reducing animal use, will be used in an upcoming Good Laboratory Practice (GLP)-compliant study for Ipsen. This collaboration highlights Charles River’s and Ipsen’s dedication and commitment to championing the 3Rs (Replacement, Reduction, and Refinement of animal use in research) while upholding the highest scientific standards. Charles River’s VCG program operates under the Alternative Methods Advancement Project™ (AMAP™), an initiative aimed at minimizing animal use in research whenever scientifically appropriate.

“This partnership exemplifies Charles River’s scientific leadership and commitment to modernizing our company and the industry,” said Dr. Namandjé N. Bumpus, Chief Scientific and Innovation Officer, Charles River. “By advancing VCGs, we are driving innovation for safety studies and reducing animal use where scientifically appropriate.”

By combining toxicology and regulatory expertise, historical control data, advanced statistical methods, and AI-powered analytics, VCGs can digitally replace a portion of concurrent control animals in safety studies. This approach lessens reliance on animal use while enhancing data clarity, offering a modern, ethical, and scientifically robust solution for developers seeking efficient decision-making. Charles River will supply VCG data to Ipsen to facilitate prospective analysis of general toxicology endpoints.

Advancing Virtual Control Groups

Virtual Control Groups may be able to impact study timelines, enhance data quality, and meet evolving regulatory expectations for the 3Rs.

  • Up to 12% reduction in animal use where scientifically appropriate, without compromising regulatory-grade rigor

  • Greater statistical power, particularly for detecting rare spontaneous findings that may otherwise obscure study outcomes

  • More consistent interpretation, leveraging large, curated historical datasets to contextualize unexpected results

As Charles River continues to advance innovative approaches through AMAP, collaborations like this demonstrate how science, technology, and expertise can work together to reduce animal use while maintaining the rigorous standards required to bring new therapies to patients.

**About the Alternative Methods Advancement Project (AMAP)**The Alternative Methods Advancement Project (AMAP) is a Charles River-led initiative dedicated to developing New Approach Methodologies (NAMs) and exploring innovative scientific and technological solutions aimed at reducing reliance on traditional animal testing. As we enter the next frontier of drug development, AMAP enables strategic, purpose-driven investment to shape a future in which more patients can access the treatments and medicines they need safely, swiftly, and successfully. AMAP is supported by our global, cross-functional Scientific Advisory Board led by Dr. Namandjé N. Bumpus.

About Charles RiverCharles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261027559748/en/

**Charles River Investor Contact:**Todd Spencer Corporate Vice President, Investor Relations 781.222.6455 [email protected]

Charles River Media Contact: Amy Cianciaruso Corporate Senior Vice President, Chief Communications Officer 781.222.6168 [email protected]

Source: Charles River Laboratories International, Inc.

Stock Quote

CRL (common)

Price

$357.55

Change (%)

-18.5475 (-4.93%)

Volume

891,344

Exchange

NYSE

Data as of 10/30/26 3:08 pm EDT Data Provided by Refinitiv. Minimum 15 minutes delayed.

Featured Reports

2025 Annual Report View PDF Print PDF

Charles River Corporate Citizenship Report View PDF Print PDF

Prompts

Charles River Laboratories International, Inc. (ticker CRL), listed in United States.

Company History

Date Change Detail
Jun 23, 2000 Renamed CHARLES RIVER LABORATORIES HOLDINGS INC → CHARLES RIVER LABORATORIES INTERNATIONAL INC

ETFs Holding Charles River Laboratories International, Inc.

ETF Weight in ETF Shares Market value As of
FCUS 3.44% 7,647 $ 2.566M Nov 17, 2026
EPSB 3.20% 702 $ 237.255K Nov 13, 2026
QMOM 2.47% 28,275 $ 9.39M Nov 18, 2026
EPSV 2.40% 418 $ 141.271K Nov 13, 2026
EPMV 2.10% 289 $ 97.673K Nov 13, 2026
BMED 1.61% 689 $ 231.173K Nov 16, 2026
TAX 1.27% 1,118 $ 322.252K Aug 31, 2026
HELX 1.26% 1,556 $ 352.885K Jun 30, 2026
GSC 1.15% 11,136 $ 3.21M Aug 31, 2026
SURE 1.07% 1,846 $ 613.167K Nov 17, 2026
JDOC 0.97% 289 $ 95.994K Nov 17, 2026
LSEQ 0.90% 435 $ 147.017K Nov 13, 2026
CGMM 0.75% 80,540 $ 27.023M Nov 16, 2026
FWD 0.73% 80,695 $ 23.26M Aug 31, 2026
BTAL short -0.53% -6,578 $ -1.492M Jun 30, 2026
MKTN 0.51% 2,405 $ 545.43K Jun 30, 2026
WCEO 0.49% 211 $ 49.06K Jul 31, 2026
TMSL 0.47% 55,675 $ 12.627M Jun 30, 2026
FFSM 0.40% 25,814 $ 6.002M Jul 31, 2026
MSSM 0.26% 6,430 $ 1.853M Aug 31, 2026
REMC 0.25% 37 $ 8,391.23 Jun 30, 2026
AVMC 0.18% 2,935 $ 984.751K Nov 16, 2026
DFAS 0.16% 154,531 $ 52.666M Nov 12, 2026
DFUV 0.09% 40,660 $ 13.857M Nov 12, 2026
DFAC 0.07% 181,963 $ 62.015M Nov 12, 2026
AAUS 0.07% 1,009 $ 340K Nov 18, 2026
CAPE 0.05% 531 $ 120.425K Jun 30, 2026
DCOR 0.03% 43,811 $ 14.931M Nov 12, 2026
DFAU 0.03% 10,472 $ 3.569M Nov 12, 2026
DFUS 0.02% 14,852 $ 5.062M Nov 12, 2026
EBI 0.02% 386 $ 111.261K Aug 31, 2026
HCMT 0.01% 332 $ 77.193K Jul 31, 2026
MSLC 0.01% 1,840 $ 530.362K Aug 31, 2026
CSHP 0.01% 79 $ 26.506K Nov 16, 2026
IALT short -0.01% -2,835 $ -951.199K Nov 16, 2026
LCTU 0.01% 406 $ 136.221K Nov 16, 2026
GSPY 0.01% 152 $ 50.999K Nov 17, 2026
DXUV 0.01% 1,160 $ 395.34K Nov 12, 2026
DFLV 0.00% 377 $ 128.485K Nov 12, 2026
DFSU 0.00% 21 $ 7,157.01 Nov 12, 2026
FMDE 0.00% 57 $ 12.927K Jun 30, 2026
AVUS 0.00% 1 $ 335.52 Nov 16, 2026
CORO 0.00% 30 $ 10.105K Nov 16, 2026
NTRL short 0.00% -245 $ 0.00 Nov 16, 2026
GVLU 0.00% 17 $ 5,703.84 Nov 17, 2026